New EMA Guideline Outlines Requirements For Potential Autism Drugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has drafted a guideline that will be of interest to companies developing or intending to develop new medicines for autism spectrum disorder (ASD), a set of disease conditions that is multifactorial, wide-ranging in its effects, and difficult to diagnose and treat effectively1.